Results 121 to 130 of about 96,176 (305)

RBD‐SD1 Nanoparticle Vaccines From DPP4‐Using Merbecoviruses Elicit a Cross‐Reactive Antibody Response but Limited Cross‐Protective Immunity

open access: yesBiotechnology and Bioengineering, EarlyView.
SpyCatcher‐mi3 nanoparticles displaying RBD‐SD1 from MERS‐CoV, NL140422, and HKU4 elicited robust and cross‐reactive IgG responses in mice. Only MERS‐CoV RBD‐SD1 induced neutralizing antibodies against MERS‐CoV and protected human DPP4 mice from a MERS‐CoV challenge, indicating conserved serologic but limited cross‐neutralizing epitopes.
Peter J. Halfmann   +9 more
wiley   +1 more source

Nanomaterial‐based immune therapeutic strategies in neurodegenerative diseases

open access: yesBMEMat, EarlyView.
This review highlights the immunomodulatory potential of nanomaterials (NMs) in treating neurodegenerative diseases (NDs). It focuses on their roles in regulating innate and adaptive immune responses to maintain immune homeostasis. By providing insights into these mechanisms, the review lays the groundwork for innovative NMs therapeutic strategies to ...
Xinru Zhou   +6 more
wiley   +1 more source

First-in-human intranasal [13N]oxytocin PET: evaluation of feasibility, biodistribution, and radiation dosimetry

open access: yesEJNMMI Research
Background Oxytocin is a neuropeptide with therapeutic potential for several neuropsychiatric and pain-related disorders. Intranasal delivery is proposed to enable access to the central nervous system via the trigeminal nerve and olfactory nerves ...
Michael Winterdahl   +6 more
doaj   +1 more source

Overcoming intranasal delivery barriers with ultrastable polyzwitterionic siRNA nanocages for enhanced glioblastoma therapy

open access: yesBMEMat, EarlyView.
A ROS‐responsive, zwitterionic nanocage enables stable, intranasal siRNA delivery to glioblastoma, promoting deep tumor penetration via non‐degradative pathways and trigeminal nerve transport. This platform achieves durable gene silencing and tumor suppression, offering a non‐invasive, storage‐stable strategy for treating glioma and other neurological ...
Jingwen Xie   +12 more
wiley   +1 more source

Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Interest in ayahuasca and its main component, N,N‐Dimethyltryptamine (DMT), has currently moved from historical and experimental use into modern clinical development. Yet, current evidence is fragmented, and systematic mapping of trial methods and design choices remains limited.
Tijana Stojanović   +4 more
wiley   +1 more source

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel   +3 more
wiley   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

open access: yesBarrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu   +9 more
wiley   +1 more source

Validation and Application of an HPLC–UV Method for the Quantification of 3‐O‐Methylquercetin in Nasal Mucosa

open access: yesELECTROPHORESIS, EarlyView.
This study improved an HPLC–UV method for quantifying 3‐O‐methylquercetin in porcine nasal mucosa following ICH M10 and ANVISA (Brazil) guidelines, assessing selectivity, linearity, accuracy, precision, and robustness. The method was applied for the first time to evaluate release, permeation, and retention profiles of a nasal formulation.
Jeniffer Viviana Ramirez Hernández   +6 more
wiley   +1 more source

Systematic statistical analysis of change in SEIzure interVAL with diazepam nasal spray supports this novel clinical endpoint for immediate‐use seizure medication

open access: yesEpilepsia, EarlyView.
Abstract Objective Appropriate endpoints for daily antiseizure medications may differ from those for intermittent, immediate‐use seizure medications (ISMs). The observed interval between seizure clusters over time (SEIzure interVAL [SEIVAL]) has been proposed as a novel effectiveness endpoint for ISMs.
Wesley T. Kerr   +4 more
wiley   +1 more source

Potentials of Intranasal Administration of Paracetamol

open access: yesNAUKA MOLODYKH (Eruditio Juvenium)
INTRODUCTION: Currently, there is an urgent issue of safe and minimally invasive administration of medical drugs ensuring rapid and selective delivery of them to the target organs. This review considers the experience of intranasal administration of drugs from different groups, such as NSAID, hormonal agents and anticonvulsants.
Yuliya A. Vlasova   +7 more
openaire   +1 more source

Home - About - Disclaimer - Privacy